Shibukawa, Japan
Shibukawa, Japan

Time filter

Source Type

Iizuka Y.,Gunma University | Iizuka Y.,Shibukawa General Hospital | Takechi R.,Gunma University | Takechi R.,Gunma Cardiovascular Center | And 4 more authors.
Skeletal Radiology | Year: 2016

We herein report two cases of atypical femoral fracture (AFF). X-ray examinations at the first visit of these two female patients showed a complete fracture of the femoral diaphysis diagnosed as an atypical femoral fracture (AFF). X-rays of these two cases also showed localized cortical thickening of the femoral diaphysis. Both patients had been taking alendronate for more than 3 years because of postmenopausal osteoporosis. We assumed that both of the fractures were associated with the long-term use of alendronate. However, we retrospectively identified localized cortical thickening of the femoral diaphysis on an X-ray taken before the alendronate therapy in both of these cases. Therefore, we suspected a pathogenesis of AFFs in which preexisting stress or an insufficient fracture unrelated to bisphosphonate (BP) therapy and subsequent suppression of bone turnover due to BP administration led to the occurrence of an AFF. The patient underwent surgery using intramedullary nails in both of these cases, followed by the administration of teriparatide, and they were able to walk without any support at the final follow-up examination. © 2016 ISS


Takeyoshi I.,Gunma University | Makita F.,National Nishi Gunma Hospital | Tanahashi Y.,Shibukawa General Hospital | Iwazaki S.,Tatebayashi Kosei Hospital | And 17 more authors.
Anticancer Research | Year: 2011

Background: Paclitaxel and doxifluridine (5′-DFUR) have distinct mechanisms of action and toxicity profiles. This study evaluated the antitumor activity and toxicities of combination chemotherapy with these drugs in patients with advanced/recurrent gastric cancer (AGC). Patients and Methods: Patients with histologically confirmed AGC, which was either unresectable or metastatic, were included in this study. The treatment consisted of 80 mg/m2 paclitaxel given i.v. on days 1, 8, and 15 every 4 weeks, and 533 mg/m 2 doxifluridine given orally on days 1-5 every week. Results: One hundred and four patients were evaluated for toxicity and 93 patients were evaluated for a therapeutic response. The overall response rate was 33.3% (1st line: 41.7%, 2nd line: 25.0%), including a complete remission in two patients, a partial remission in 29, stable disease in 39, progressive disease in 17; the response was not evaluable in six patients. The median overall survival was 287 days. Commonly observed grade 3/4 adverse events were leukopenia (13.5%), anorexia (3.8%), fatigue (3.8%) and diarrhea (2.9%). Conclusion: Paclitaxel and doxifluridine combination chemotherapy is a well-tolerated and convenient treatment regimen that can be given on an outpatient basis with promising efficacy for AGC.


Takeyoshi I.,Gunma University | Takeyoshi I.,Nishi Gunma National Hospital | Makita F.,Nishi Gunma National Hospital | Iwazaki S.,Tatebayashi Kosei Hospital | And 17 more authors.
Anticancer Research | Year: 2011

Background: The efficacy of systemic chemotherapy for peritoneal dissemination of gastric cancer remains unclear. The efficacy of weekly paclitaxel in combination with doxifluridine (5′-DFUR) in gastric cancer patients with malignant ascites was evaluated. Patients and Methods: Patients with histologically confirmed gastric cancer with ascites were eligible. The treatment consisted of paclitaxel intravenously (i.v.) administered at 80 mg/m 2 on days 1, 8 and 15 every 4 weeks, and doxifluridine administered orally at 533 mg/m 2 on days 1-5 every week. The response rate for patients with ascites was determined based on the Japanese Classification of Gastric Carcinoma. Also, the concentration of paclitaxel in the ascites was measured. Results: Twenty-four patients were investigated. The response rate (RR) was 41.7%, including complete remission (CR) and partial remission (PR) in 4 and 6 patients, respectively. The concentration of paclitaxel in the ascites was maintained between 0.01 μM and 0.05 μM until 72 hours. The median overall survival (OS) was 215 days, and 1-year survival rate was 29.2%. No severe toxicity was noted. Conclusion: Weekly paclitaxel in combination with doxifluridine is effective for gastric cancer patients with malignant ascites with an acceptable toxicity profile.


Kasahara Y.,Fukui Saiseikai Hospital | Kawai M.,Tohoku University | Tsuji I.,Tohoku University | Tohno E.,University of Tsukuba | And 4 more authors.
Breast Cancer | Year: 2013

Background The US Preventative Services Task Force assesses the efficacy of breast cancer screening by the sum of its benefits and harms, and recommends against routine screening mammography because of its relatively great harms for women aged 40-49 years. Assessment of the efficacy of screening mammography should take into consideration not only its benefits but also its harms, but data regarding those harms are lacking for Japanese women. Methods In 2008 we collected screening mammography data from 144,848 participants from five Japanese prefectures by age bracket to assess the harms [false-positive results, performance of unnecessary additional imaging, fine-needle aspiration cytology (FNA), and biopsy and its procedures]. Results The rate of cancer detected in women aged 40-49 years was 0.28%. The false-positive rate (9.6%) and rates of additional imaging by mammography (5.8%) and ultrasound (7.3%) were higher in women aged 40-49 years than in the other age brackets. The rates of FNA (1.6%) and biopsy (0.7%) were also highest in women aged 40-49 years. However, they seemed to be lower than the rates reported by the Breast Cancer Surveillance Consortium (BCSC) and other studies in the US. Conclusions The results, although preliminary, indicate the possibility that the harms of screening mammography for Japanese women are less than those for American women. © The Japanese Breast Cancer Society 2012.


Nakazawa K.,Saitama Sekishinkai Hospital | Kanda K.,Gunma University | Kyota A.,Palliative Care Clinic Ippo | Honda M.,Shibukawa General Hospital
Kitakanto Medical Journal | Year: 2014

Purpose: The objective of this study was to reveal the impact of oxaliplatin-induced persistent peripheral neuropathy on the social life of colorectal cancer patients and to review their care and available support services. Patients and Methods: Data was collected from 19 colorectal cancer outpatients treated with oxaliplatin (≥850mg/m2 in total) using semi-structured interviews, and the results were analyzed qualitatively and inductively. Results: The results revealed that the impacts of persistent peripheral neuropathy on the social life of colorectal cancer patients could be classified into the following 5 interrelated categories: "fear of the collapse of the foundation of their social life", "dependence and independence in activities of life associated with relationships with others", "fluctuation of self-concept in relation to other people", "deepening of intimacy triggered by numbness", and "numbness as a threat to the value of one's own existence". Conclusions: A hierarchy in the effects of persistent peripheral neuropathy on social life was observed, and the effects of neuropathy, including both mental and spiritual aspects, should therefore be considered in totality. Our study suggested that the comprehensive assessment of patients' persistent peripheral neuropathy is important.


Kurabayashi M.,Shibukawa General Hospital | Tanahashi Y.,Shibukawa General Hospital | Okano T.,Shibukawa General Hospital | Ohki S.,Shibukawa General Hospital | And 3 more authors.
Kitakanto Medical Journal | Year: 2012

A 62-year-old male presented with appetite loss, abdominal fullness, tarry stool, and vertigo. Gastrointestinal endoscopy showed advanced gastric cancer, type 3, which was diagnosed as poorly differentiated adenocarcinoma with severe pyloric stenosis. Computed tomography (CT) showed hugely enlarged lymph nodes in the para-aortic region. He was diagnosed with gastric cancer stage IV and treated with paclitaxel chemotherapy weekly. However, the treatment was ineffective. A nasogastric tube was required for persistent vomiting with gastric outlet obstruction. We recommended a gastroje-junostomy bypass operation, but the patient refused. After obtaining informed consent, a WallFlex stent was inserted, but did not relieve the obstruction. Endoscopy showed that the stent was obstructed with tumor ingrowth. An UltraFlex covered stent was inserted within the WallFlex stent and was effective. Subsequently, the patient was able to eat solid food for 9 months, received chemotherapy, and died 11 months after stent insertion. Stent therapy should be considered for palliative care in gastric outlet obstruction caused by gastric cancer.

Loading Shibukawa General Hospital collaborators
Loading Shibukawa General Hospital collaborators